Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | TACR3 | P29371 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15716619 | 1.00 | TAS1R3 (0.54) | TAS1R3TAS1R1TACR3LMNATSHR | |
| SCHEMBL4490832 | 0.86 | TAS1R3 (0.60) | TAS1R3TAS1R1TACR3TSHRROCK2 | |
| SCHEMBL7723793 | 0.85 | TAS1R3 (0.56) | TAS1R3TAS1R1TACR3LMNATSHR | |
| SCHEMBL7723790 | 0.85 | TAS1R3 (0.56) | TAS1R3TAS1R1TACR3LMNATSHR | |
| SCHEMBL792022 | 0.85 | TAS1R3 (0.56) | TAS1R3TAS1R1TACR3LMNATSHR | |
| SCHEMBL16965057 | 0.84 | MAPK1 (0.49) | MAPK1 | |
| SCHEMBL16965472 | 0.84 | MAPK1 (0.49) | MAPK1 | |
| SCHEMBL16965332 | 0.84 | MAPK1 (0.49) | MAPK1 | |
| SCHEMBL18943197 | 0.83 | TAS1R3 (0.54) | TAS1R3TAS1R1TACR3TSHRROCK2 | |
| SCHEMBL14186870 | 0.83 | TAS1R3 (0.54) | TAS1R3TAS1R1TACR3TSHRROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233858-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-2900241-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2900241-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2770987-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| EP-2900223-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2900223-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3233858-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| WO-2016100050-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | US | disclosed |
| EP-2900241-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2900223-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| US-9023865-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140296203-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| EP-2770987-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013063214-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296203-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK10, MAP3K1 | TAS1R3 4202/4885TAS1R1 3650/4885TACR3 3487/4885 |
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | TAS1R3 4475/4885TAS1R1 3974/4885TACR3 3280/4885 |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK10, MAP3K1 | TAS1R3 4202/4885TAS1R1 3650/4885TACR3 3487/4885 |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAP3K20 | TAS1R3 3404/4885TAS1R1 2587/4885TACR3 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.